Clyde Bailey

Director of Bioinformatics

University of Arkansas for Medical Sciences

faculty

14 h-index 94 pubs 1,901 cited

Research Areas

Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Immune Response and Inflammation Cancer Genomics and Diagnostics Bioinformatics and Genomic Networks Hematopoietic Stem Cell Transplantation Immune Cell Function and Interaction

Links

ORCID Lab Website

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Clyde Bailey's research focuses on the molecular and cellular mechanisms underlying multiple myeloma and related hematologic malignancies. His work investigates the tumor microenvironment, identifying key molecular players such as NEK2 in suppressing T cell immunity. Bailey also studies prognostic markers and risk stratification for multiple myeloma, including the development of gene signatures to predict disease progression from precursor stages like MGUS. His research extends to treatment strategies, evaluating outcomes of stem cell transplantation and maintenance therapies. Bailey collaborates with several researchers at the University of Arkansas for Medical Sciences, including John D. Shaughnessy Jr., Guido Tricot, David E. Mery, and Cody Ashby, with whom he has co-authored numerous publications. He has a publication record of 94 papers and a citation count of 1,901, with an h-index of 14.

Metrics

h-index: 14
Publications: 94
Citations: 1,901

Selected Publications

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025) DOI
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024) DOI
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024) DOI
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023) DOI
Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease (2023) DOI
Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma (2023) DOI
A 5-Stage System for ASCT Multiple Myeloma (2023) DOI
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023) DOI